PL2697223T3 - Pochodne kwasu 7-(heteroaryloamino)-6,7,8,9-tetrahydropirydo[1,2-a]indolooctowego i ich zastosowanie jako modulatorów receptora prostaglandyny D2 - Google Patents

Pochodne kwasu 7-(heteroaryloamino)-6,7,8,9-tetrahydropirydo[1,2-a]indolooctowego i ich zastosowanie jako modulatorów receptora prostaglandyny D2

Info

Publication number: PL2697223T3
Authority: PL; Poland
Prior art keywords: tetrahydropyrido; prostaglandin; heteroaryl; amino; acetic acid
Prior art date: 2011-04-14

Application number

PL12722194T

Other languages

English (en)

Inventor

Hamed Aissaoui

Christoph Boss

Jerome Gabillet

Sylvia Richard-Bildstein

Romain Siegrist

Original Assignee

Actelion Pharmaceuticals Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-14

Filing date

2012-04-13

Publication date

2017-01-31

2012-04-13 Application filed by Actelion Pharmaceuticals Ltd. filed Critical Actelion Pharmaceuticals Ltd.

2017-01-31 Publication of PL2697223T3 publication Critical patent/PL2697223T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Hematology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Otolaryngology (AREA)
Diabetes (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PL12722194T 2011-04-14 2012-04-13 Pochodne kwasu 7-(heteroaryloamino)-6,7,8,9-tetrahydropirydo[1,2-a]indolooctowego i ich zastosowanie jako modulatorów receptora prostaglandyny D2 PL2697223T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IB2011051615		2011-04-14

Publications (1)

Publication Number	Publication Date
PL2697223T3 true PL2697223T3 (pl)	2017-01-31

Family

ID=46125478

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL12722194T PL2697223T3 (pl)	2011-04-14	2012-04-13	Pochodne kwasu 7-(heteroaryloamino)-6,7,8,9-tetrahydropirydo[1,2-a]indolooctowego i ich zastosowanie jako modulatorów receptora prostaglandyny D2

Country Status (28)

Country	Link
US (1)	US9096595B2 (pl)
EP (1)	EP2697223B1 (pl)
JP (1)	JP5964945B2 (pl)
KR (1)	KR101928595B1 (pl)
CN (1)	CN103459389B (pl)
AU (1)	AU2012241442B2 (pl)
BR (1)	BR112013026283A8 (pl)
CA (1)	CA2830204C (pl)
CL (1)	CL2013002832A1 (pl)
CY (1)	CY1118084T1 (pl)
DK (1)	DK2697223T3 (pl)
ES (1)	ES2596581T3 (pl)
HR (1)	HRP20161235T1 (pl)
HU (1)	HUE028972T2 (pl)
IL (1)	IL228820A (pl)
LT (1)	LT2697223T (pl)
MA (1)	MA35102B1 (pl)
MX (1)	MX338516B (pl)
MY (1)	MY165623A (pl)
PH (1)	PH12013501938A1 (pl)
PL (1)	PL2697223T3 (pl)
PT (1)	PT2697223T (pl)
RU (1)	RU2596823C2 (pl)
SG (1)	SG193902A1 (pl)
SI (1)	SI2697223T1 (pl)
UA (1)	UA110245C2 (pl)
WO (1)	WO2012140612A1 (pl)
ZA (1)	ZA201308497B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR080703A1 (es)	2010-03-22	2012-05-02	Actelion Pharmaceuticals Ltd	Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma.
EP3119779B1 (en)	2014-03-17	2018-07-11	Idorsia Pharmaceuticals Ltd	Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
ES2699379T3 (es)	2014-03-18	2019-02-11	Idorsia Pharmaceuticals Ltd	Derivados de ácido azaindol acético y su uso como moduladores del receptor de prostaglandina D2
AU2016323262B2 (en)	2015-09-15	2020-11-19	Idorsia Pharmaceuticals Ltd	Crystalline forms

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4808608A (en)	1986-01-23	1989-02-28	Merck & Co., Inc.	Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
DE3631824A1 (de)	1986-02-21	1988-03-31	Bayer Ag	Cycloalkano(1.2-b)indol-sulfonamide
IL129484A0 (en) *	1998-04-17	2000-02-29	Lilly Co Eli	Substituted tricyclics
US20010047027A1 (en)	2000-04-12	2001-11-29	Marc Labelle	Prostaglandin D2 receptor antagonists
AU2001250206A1 (en)	2000-04-12	2001-10-30	Merck Frosst Canada Ltd	Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
DE60215000T2 (de)	2001-05-23	2007-08-09	Merck Frosst Canada & Co, Kirkland	Dihydropyrroloil[1,2-a]indol- und Tetrahydropyridol[1,2-a]indol-Derivate als Prostaglandin-D2-Rezeptor-Antagonisten
WO2003051837A2 (de)	2001-12-14	2003-06-26	Zentaris Gmbh	Tetrahydrocarbazolderivate als liganden für g-protein gekoppelte rezeptoren (gpcr)
AR038136A1 (es)	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
SE0200411D0 (sv)	2002-02-05	2002-02-05	Astrazeneca Ab	Novel use
SE0200356D0 (sv)	2002-02-05	2002-02-05	Astrazeneca Ab	Novel use
AU2003231513A1 (en)	2002-05-16	2003-12-02	Shionogi And Co., Ltd.	Pgd2 receptor antagonist
US7534897B2 (en)	2002-05-16	2009-05-19	Shionogi & Co., Ltd.	Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
GB2388540A (en)	2002-05-17	2003-11-19	Bayer Ag	New use of Ramatroban
TW200307542A (en)	2002-05-30	2003-12-16	Astrazeneca Ab	Novel compounds
SE0201635D0 (sv)	2002-05-30	2002-05-30	Astrazeneca Ab	Novel compounds
SE0202241D0 (sv)	2002-07-17	2002-07-17	Astrazeneca Ab	Novel Compounds
EP1558614B1 (en)	2002-10-30	2010-09-01	Merck Frosst Canada Ltd.	Pyridopyrrolizine and pyridoindolizine derivatives
WO2004078719A1 (ja)	2003-03-06	2004-09-16	Ono Pharmaceutical Co., Ltd.	インドール誘導体化合物およびその化合物を有効成分とする薬剤
US20070054951A1 (en)	2003-05-20	2007-03-08	Lianhai Li	Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
SE0301569D0 (sv)	2003-05-27	2003-05-27	Astrazeneca Ab	Novel compounds
AU2004247285A1 (en)	2003-06-12	2004-12-23	Merck Frosst Canada Ltd	Cycloalkanepyrrolopyridines as DP receptor antagonists
SE0302232D0 (sv)	2003-08-18	2003-08-18	Astrazeneca Ab	Novel Compounds
WO2005033099A2 (en)	2003-10-03	2005-04-14	Glenmark Pharmaceuticals Ltd.	Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
WO2005040112A1 (en)	2003-10-14	2005-05-06	Oxagen Limited	Compounds with pgd2 antagonist activity
US20070232681A1 (en)	2003-10-14	2007-10-04	Oxagen Limited	Compounds Having Crth2 Antagonist Activity
GB2407318A (en)	2003-10-23	2005-04-27	Oxagen Ltd	Substituted Indol-3-yl acetic acid derivatives
GB0324763D0 (en)	2003-10-23	2003-11-26	Oxagen Ltd	Use of compounds in therapy
SE0303180D0 (sv)	2003-11-26	2003-11-26	Astrazeneca Ab	Novel compounds
US7019022B2 (en)	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
RU2373208C2 (ru)	2004-01-31	2009-11-20	Актимис Фармасьютикалз, Инк.	Производные имидазо[1,2-c]пиримидинилуксусной кислоты
ES2345662T3 (es)	2004-03-11	2010-09-29	Actelion Pharmaceuticals Ltd.	Derivados de acido indol-1-il-acetico.
PT1725553E (pt)	2004-03-11	2008-07-16	Actelion Pharmaceuticals Ltd	Derivados de tetra-hidropiridoindole
US20050234030A1 (en)	2004-04-20	2005-10-20	Wilmin Bartolini	Modulators of CRTH2, COX-2 and FAAH
GB0412914D0 (en)	2004-06-10	2004-07-14	Oxagen Ltd	Compounds
MY144903A (en)	2004-06-17	2011-11-30	Novartis Ag	Pyrrolopyridine derivatives and their use as crth2 antagonists
WO2006034418A2 (en)	2004-09-21	2006-03-30	Athersys, Inc.	Benzimidazole acetic acids exhibiting crth2 receptor antagonism and uses thereof
WO2006034419A2 (en)	2004-09-21	2006-03-30	Athersys, Inc.	Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof
GB0427381D0 (en)	2004-12-14	2005-01-19	Novartis Ag	Organic compounds
ATE518834T1 (de)	2004-12-27	2011-08-15	Actelion Pharmaceuticals Ltd	2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
DOP2006000016A (es)	2005-01-26	2006-07-31	Aventis Pharma Inc	2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
GB2422831A (en)	2005-02-04	2006-08-09	Oxagen Ltd	Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB2422829A (en)	2005-02-04	2006-08-09	Oxagen Ltd	Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB2422830A (en)	2005-02-04	2006-08-09	Oxagen Ltd	Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
MX2007010112A (es)	2005-02-25	2007-10-12	Ono Pharmaceutical Co	Compuesto indol y uso del mismo.
GB0504150D0 (en)	2005-03-01	2005-04-06	Oxagen Ltd	Microcrystalline material
GB0505048D0 (en)	2005-03-11	2005-04-20	Oxagen Ltd	Compounds with PGD antagonist activity
ZA200709819B (en)	2005-05-24	2009-09-30	Serono Lab	Tricyclic spiro derivatives as CRTH2 modulators
GB0512944D0 (en)	2005-06-24	2005-08-03	Argenta Discovery Ltd	Indolizine compounds
WO2007010964A1 (ja)	2005-07-22	2007-01-25	Shionogi & Co., Ltd.	Ｐｇｄ２受容体アンタゴニスト活性を有するインドール誘導体
JP5064219B2 (ja)	2005-07-22	2012-10-31	塩野義製薬株式会社	Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
ES2443022T3 (es) *	2005-08-12	2014-02-17	Merck Frosst Canada Inc.	Derivados de indol como antagonistas del receptor CRTH2
WO2007022501A2 (en)	2005-08-18	2007-02-22	Microbia, Inc.	Useful indole compounds
EP1932839A4 (en)	2005-09-06	2014-09-10	Shionogi & Co	INDOLECARBOXYLATE ACID DERIVATIVE HAVING ANTAGONIST EFFECT OF THE PGD2 RECEPTOR
GB0518783D0 (en)	2005-09-14	2005-10-26	Argenta Discovery Ltd	Indolizine compounds
GB0521275D0 (en)	2005-10-19	2005-11-30	Argenta Discovery Ltd	3-Aminoindole compounds
GB0525141D0 (en)	2005-12-09	2006-01-18	Novartis Ag	Organic compounds
GB0525143D0 (en)	2005-12-09	2006-01-18	Novartis Ag	Organic compounds
GB0525144D0 (en)	2005-12-09	2006-01-18	Novartis Ag	Organic compounds
GB0525337D0 (en)	2005-12-13	2006-01-18	Novartis Ag	Organic compounds
GB0605743D0 (en)	2006-03-22	2006-05-03	Oxagen Ltd	Salts with CRTH2 antagonist activity
US7741360B2 (en)	2006-05-26	2010-06-22	Astrazeneca Ab	Bi-aryl or aryl-heteroaryl substituted indoles
GB0611695D0 (en)	2006-06-13	2006-07-26	Novartis Ag	Organic compounds
KR20090042808A (ko)	2006-07-22	2009-04-30	옥사겐 리미티드	씨알티에이치2 길항제 활성을 갖는 화합물
PT2066628E (pt)	2006-07-25	2010-12-31	Sanofi Aventis	2-fenil-indoles como antagonistas do receptor da prostaglandina d2
JP5220013B2 (ja) *	2006-08-07	2013-06-26	アクテリオンファーマシューティカルズリミテッド	（３−アミノ−１，２，３，４−テトラヒドロ−９ｈ−カルバゾール−９−イル）−酢酸誘導体
AU2006352195A1 (en)	2006-12-21	2008-06-26	Argenta Discovery Limited	CRTH2 antagonists
GB0625842D0 (en)	2006-12-22	2007-02-07	Argenta Discovery Ltd	Indolizine derivatives
CA2681409A1 (en)	2007-03-21	2008-09-25	Argenta Oral Therapeutics Limited	Indolizine acetic acid derivatives as crth2 antagonists
GB0719485D0 (en)	2007-10-05	2007-11-14	Argenta Discovery Ltd	Compounds
GB0719521D0 (en)	2007-10-05	2007-11-14	Argenta Discovery Ltd	Compounds
EP2197438B1 (en)	2007-10-10	2015-07-15	Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.	Heterocyclic compounds as crth2 receptor antagonists
WO2009061676A2 (en)	2007-11-06	2009-05-14	Amira Pharmaceuticals, Inc.	Antagonists of pgd2 receptors
GB0722216D0 (en)	2007-11-13	2007-12-27	Oxagen Ltd	Use of crth2 antagonist compounds
GB0722203D0 (en)	2007-11-13	2007-12-19	Oxagen Ltd	Use of CRTH2 antagonist compounds
DK2229358T3 (da)	2007-12-14	2011-07-04	Pulmagen Therapeutics Asthma Ltd	Indoler og deres terapeutiske anvendelse
KR101644170B1 (ko)	2008-01-18	2016-08-01	옥사겐 리미티드	씨알티에이치2 길항제 활성을 갖는 화합물
JP2011509985A (ja)	2008-01-18	2011-03-31	プルマジェンセラピューティクス（アズマ）リミテッド	Ｃｒｔｈ２受容体に対して活性なインドール
US7750027B2 (en)	2008-01-18	2010-07-06	Oxagen Limited	Compounds having CRTH2 antagonist activity
JP2011509990A (ja)	2008-01-22	2011-03-31	オキサジェンリミテッド	Ｃｒｔｈ２アンタゴニスト活性を有する化合物
EP2240444A1 (en)	2008-01-22	2010-10-20	Oxagen Limited	Compounds having crth2 antagonist activity
JP2011088826A (ja)	2008-01-31	2011-05-06	Astellas Pharma Inc	芳香族カルボン酸化合物
US20110112134A1 (en)	2008-05-16	2011-05-12	Amira Pharmaceuticals, Inc.	Tricyclic Antagonists of Prostaglandin D2 Receptors
EP2300425A4 (en)	2008-06-24	2012-03-21	Panmira Pharmaceuticals Llc	PROSTAGLANDIN D2 RECEPTOR CYCLOALCANEÝBINDLUCK ANTAGONISTS
CA2730390A1 (en)	2008-07-15	2010-01-21	F.Hoffmann-La Roche Ag	Aminotetrahydroindazoloacetic acids
CN102099342B (zh)	2008-07-15	2013-07-10	霍夫曼-拉罗奇有限公司	氨基四氢吲唑基乙酸类
US8546422B2 (en)	2008-09-22	2013-10-01	Merck Canada Inc.	Azaindole derivatives as CRTH2 receptor antagonists
AU2009295230A1 (en)	2008-09-22	2010-03-25	Merck Canada Inc.	Indole derivatives as CRTH2 receptor antagonists
JP2012502926A (ja)	2008-09-22	2012-02-02	メルクカナダインコーポレイテッド	Ｃｒｔｈ２受容体アンタゴニストとしてのインドール誘導体
US20110312945A1 (en)	2008-10-01	2011-12-22	James Jia	Crth2 modulators
GB2465062B (en)	2008-11-06	2011-04-13	Amira Pharmaceuticals Inc	Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2010085820A2 (en)	2009-01-26	2010-07-29	Amira Pharmaceuticals, Inc.	Tricyclic compounds as antagonists of prostaglandin d2 receptors
PT2401269E (pt) *	2009-02-24	2014-03-11	Merck Canada Inc	Derivados de indol como antagonistas de recetor crth2
WO2010142934A1 (en)	2009-06-12	2010-12-16	Pulmagen Therapeutics (Asthma) Limited	Indole derivatives as ligands of crth2 receptors
US20120115895A1 (en)	2009-07-15	2012-05-10	Merck Serono S.A.	Tricyclic indole-derived spiro derivatives as crth2 modulators
WO2011055270A1 (en)	2009-11-04	2011-05-12	Wyeth Llc	Indole based receptor crth2 antagonists
AR080703A1 (es) *	2010-03-22	2012-05-02	Actelion Pharmaceuticals Ltd	Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma.
US20110311483A1 (en)	2010-03-30	2011-12-22	Ironwood Pharmaceuticals, Inc.	Crth2 modulators
US20130216552A1 (en)	2010-07-12	2013-08-22	Ironwood Pharmaceuticals, Inc.	Crth2 modulators
WO2012009134A1 (en)	2010-07-12	2012-01-19	Ironwood Pharmaceuticals, Inc.	Crth2 modulators

2012
- 2012-04-13 PL PL12722194T patent/PL2697223T3/pl unknown
- 2012-04-13 BR BR112013026283A patent/BR112013026283A8/pt not_active Application Discontinuation
- 2012-04-13 KR KR1020137029940A patent/KR101928595B1/ko not_active Expired - Fee Related
- 2012-04-13 US US14/111,889 patent/US9096595B2/en not_active Expired - Fee Related
- 2012-04-13 HU HUE12722194A patent/HUE028972T2/en unknown
- 2012-04-13 MX MX2013011937A patent/MX338516B/es active IP Right Grant
- 2012-04-13 LT LTEP12722194.3T patent/LT2697223T/lt unknown
- 2012-04-13 WO PCT/IB2012/051831 patent/WO2012140612A1/en not_active Ceased
- 2012-04-13 PH PH1/2013/501938A patent/PH12013501938A1/en unknown
- 2012-04-13 CN CN201280017738.8A patent/CN103459389B/zh not_active Expired - Fee Related
- 2012-04-13 SG SG2013068218A patent/SG193902A1/en unknown
- 2012-04-13 RU RU2013150527/04A patent/RU2596823C2/ru not_active IP Right Cessation
- 2012-04-13 UA UAA201313118A patent/UA110245C2/ru unknown
- 2012-04-13 ES ES12722194.3T patent/ES2596581T3/es active Active
- 2012-04-13 MY MYPI2013701918A patent/MY165623A/en unknown
- 2012-04-13 SI SI201230706A patent/SI2697223T1/sl unknown
- 2012-04-13 AU AU2012241442A patent/AU2012241442B2/en not_active Ceased
- 2012-04-13 JP JP2014504437A patent/JP5964945B2/ja not_active Expired - Fee Related
- 2012-04-13 PT PT127221943T patent/PT2697223T/pt unknown
- 2012-04-13 EP EP12722194.3A patent/EP2697223B1/en not_active Not-in-force
- 2012-04-13 HR HRP20161235TT patent/HRP20161235T1/hr unknown
- 2012-04-13 DK DK12722194.3T patent/DK2697223T3/en active
- 2012-04-13 CA CA2830204A patent/CA2830204C/en not_active Expired - Fee Related
2013
- 2013-10-01 CL CL2013002832A patent/CL2013002832A1/es unknown
- 2013-10-10 IL IL228820A patent/IL228820A/en active IP Right Grant
- 2013-11-07 MA MA36397A patent/MA35102B1/fr unknown
- 2013-11-13 ZA ZA2013/08497A patent/ZA201308497B/en unknown
2016
- 2016-10-11 CY CY20161101009T patent/CY1118084T1/el unknown

Also Published As

Publication number	Publication date
AU2012241442A1 (en)	2013-12-05
NZ617624A (en)	2015-05-29
SG193902A1 (en)	2013-11-29
HRP20161235T1 (hr)	2016-11-04
MA35102B1 (fr)	2014-05-02
CA2830204C (en)	2019-04-09
JP5964945B2 (ja)	2016-08-03
LT2697223T (lt)	2016-10-10
JP2014510784A (ja)	2014-05-01
KR20140025455A (ko)	2014-03-04
MX338516B (es)	2016-04-20
IL228820A0 (en)	2013-12-31
BR112013026283A8 (pt)	2018-01-30
KR101928595B1 (ko)	2018-12-12
MY165623A (en)	2018-04-18
CA2830204A1 (en)	2012-10-18
DK2697223T3 (en)	2016-09-05
ES2596581T3 (es)	2017-01-10
BR112013026283A2 (pt)	2017-01-24
US20140045870A1 (en)	2014-02-13
HUE028972T2 (en)	2017-01-30
SI2697223T1 (sl)	2016-10-28
MX2013011937A (es)	2014-03-27
PH12013501938A1 (en)	2017-05-19
RU2596823C2 (ru)	2016-09-10
RU2013150527A (ru)	2015-05-20
CN103459389B (zh)	2016-03-30
UA110245C2 (xx)	2015-12-10
US9096595B2 (en)	2015-08-04
EP2697223A1 (en)	2014-02-19
EP2697223B1 (en)	2016-07-13
CY1118084T1 (el)	2017-06-28
CN103459389A (zh)	2013-12-18
WO2012140612A1 (en)	2012-10-18
CL2013002832A1 (es)	2014-05-23
PT2697223T (pt)	2016-10-14
IL228820A (en)	2017-12-31
ZA201308497B (en)	2017-11-29
AU2012241442B2 (en)	2017-01-12

Publication	Publication Date	Title
PT2740476T (pt)	2019-03-18	Derivados cis-tetra-hidro-espiro (ciclo-hexano-1,1'- pirido [3,4-b] indole) -4-amina
IL227526A0 (en)	2013-09-30	Derivatives of 6-cyclobutyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidine-4-one and their use as a9pde inhibitors
EP2424366A4 (en)	2012-12-19	PYRIDO [4.3-B] INDOLES AND THEIR METHODS OF USE
EP2424364A4 (en)	2012-12-19	PYRIDO [4.3-B] INDOLES AND METHODS OF USE
EP2480080A4 (en)	2014-01-08	PYRIDO [3,4-B] INDOLES AND METHODS OF USE
SG11201402197UA (en)	2014-09-26	[1, 2, 3] triazolo [4, 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
EP2480078A4 (en)	2013-03-06	PYRIDO- [4,3-B] INDOLE AND USE METHOD THEREFOR
PT2935274T (pt)	2018-12-05	Derivados de 3-oxo-2,3,5,8-tetrahidro-[1,2,4]triazolo[4,3- a]pirimidina para o tratamento de doenças respiratórias
IL232304A (en)	2016-02-29	[3,2,1] triazolo [5,4– d] pyrimidine derivatives as cannabinoid receptor type 2 agonists [3,2,1] triazolo [5,4– d] pyrimidine as cannabinoid receptor 2 agonists
IL229993A0 (en)	2014-01-30	A process for the preparation of 8-Alkoxy[1,2,4]triazolo[5,1-c]pyrimidine-2 amines 5-converted
IL221479A0 (en)	2012-10-31	Triazolo [4,5-b] pyridin derivatives
ZA201308497B (en)	2017-11-29	7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
PT2729471E (pt)	2015-09-16	Derivados do ácido carboxílico com um anel de oxazolo[5,4-d pirimidina
HK1194379A (en)	2014-10-17	7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP2651937B8 (en)	2016-07-13	Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy
PT2729473E (pt)	2016-03-22	Derivados de ácido carboxílico com um anel oxazolo[5,4-b]piridina
PL390846A1 (pl)	2011-10-10	Pochodne 5,11-dimetylo-5H-indolo[2,3-b]chinoliny
EP2729475B8 (de)	2015-08-26	Carbonsäurederivate mit einem oxazolo[5,4-d]pyrimidinring
PL394218A1 (pl)	2012-09-24	Nowe zwiazki, pochodne pirydo[2",3":5', 6']pirazyno[2', 3' : 5,6][1,4]ditiino[2,3-b]chinoksaliny oraz sposób ich wytwarzania
HK1167998A (en)	2012-12-21	Pyrido [4, 3-b] indoles and methods of use
HK1167997A (en)	2012-12-21	Pyrido [4,3-b] indoles and methods of use
HK1179251A (en)	2013-09-27	Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof